首页> 外国专利> METHOD OF PREDICTING AND DETERMINING THERAPEUTIC EFFECT ON RHEUMATOID ARTHRITIS DUE TO BIOLOGICAL FORMULATION

METHOD OF PREDICTING AND DETERMINING THERAPEUTIC EFFECT ON RHEUMATOID ARTHRITIS DUE TO BIOLOGICAL FORMULATION

机译:预测和确定生物制剂对类风湿关节炎的治疗作用的方法

摘要

The present invention provides a method of predicting and determining a therapeutic effect (especially whether complete remission is reached) or the level of improvement prior to administration of a biological formulation such as an anti-IL-6 agent or an anti-TNF-α agent, which is simple and cost-effective, and accurate. Sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, MIP-1α and the like can be utilized as a specific marker used in the method. Since a therapeutic effect (level of improvement in a symptom or possibility of remission) on a rheumatoid arthritis patient can be determined prior to the administration of a biological formulation using such a specific marker, rheumatoid arthritis therapy is possible at a precision that could not be achieved conventionally.
机译:本发明提供了在施用生物制剂例如抗IL-6剂或抗TNF-α剂之前预测和确定治疗效果(特别是是否达到完全缓解)或改善水平的方法。 ,简单,经济,准确。 Sgp130,IP-10,sTNFRI,sTNFRII,GM-CSF,IL-1β,IL-2,IL-5,IL-6,IL-7,IL-8,IL-9,IL-10,IL-12, IL-13,IL-15,嗜酸性粒细胞趋化因子,VEGF,MCP-1,TNF-α,IFN-γ,FGFbasic,PDGF-bb,sIL-6R,MIP-1α等可以用作在方法。由于可以在使用这样的特异性标记物施用生物制剂之前确定对类风湿性关节炎患者的治疗效果(症状的改善水平或缓解的可能性),因此类风湿性关节炎疗法的精确度是不可能的。按常规实现。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号